Low-Dose Alteplase During Primary Percutaneous Coronary Intervention According to Ischemic Time
Peter J. McCartney, Annette M. Maznyczka, Hany Eteiba, Margaret McEntegart, Keith G. Oldroyd, John P. Greenwood, Neil Maredia, Matthias Schmitt, Gerry P. McCann, Timothy Fairbairn, Elisa McAlindon, Campbell Tait, Paul Welsh, Naveed Sattar, Vanessa Orchard, David Corcoran, Thomas J. Ford, Aleksandra Radjenovic, Ian Ford, Alex McConnachie, Colin Berry and for the T-TIME Investigators
Efficacy of Intracoronary Alteplase and Mechanism of Increased Microvascular Injury in Patients With an Ischemic Time of ≥4 to 6 h
The flow diagram groups participants by ischemic time into 3 categories (≥4 to 6 h, n = 98; ≥2 but <4 h, n = 235; <2 h, n = 107), those with an ischemic time of 4 h or more are subgrouped according to treatment group allocation (placebo, n = 29; 10 mg alteplase n = 38; 20 mg alteplase, n = 31). The effect of intracoronary alteplase on the extent of microvascular obstruction and myocardial hemorrhage is shown, including the effect estimates. The estimated mean difference on a square root scale is shown for the extent of microvascular obstruction and the estimated mean difference for myocardial hemorrhage. There was a statistically significant increase in microvascular obstruction and myocardial hemorrhage extent in those patients receiving alteplase. CI = confidence interval.